Drug intelligence / Profile preview

AMP-1915 (Shanghai University of Traditional Chinese Medicine)

Development stage: Unknown
Lead developer: Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

**AMP-1915** is an investigator-designated traditional Chinese herbal medicine formula, also called Huangqisan, developed by Shanghai University of Traditional Chinese Medicine for metabolic syndrome. The formula contains Radix Astragali, Radix Puerariae, and Cortex Mori; it was administered as a traditional Chinese formula extract mixed into instant noodles in a randomized, double-blind, placebo-controlled clinical study. Its molecular targets and pharmacological mechanism have not been publicly specified. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02605655))

Other names: Huangqi SanHuangqisan

Beyond the preview

Go deeper on AMP-1915 (Shanghai University of Traditional Chinese Medicine).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMP-1915 (Shanghai University of Traditional Chinese Medicine).

Explore the full profile